iPSC-derived allogeneic NK cell therapy (Fate Therapeutics/University of Minnesota)

N/A

Report date: 2025/03/20 16:04:41

Base Information

Drug NameiPSC-derived allogeneic NK cell therapy (Fate Therapeutics/University of Minnesota)
Drug Alias NameCD64/16A-expressing iPSC-derived NK cell therapy (Fate Therapeutics/University of Minnesota)iNK-CD64/16Aallogenic natural killer cell therapy (Fate Therapeutics/University of Minnesota)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionImmunostimulantsNatural killer cells stimulants
TargetsUpdating
Therapy Area/IndicationsOvarian NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Minnesota
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of MinnesotaFate Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsOvarian Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A